Blockchain Registration Transaction Record

Tonix Pharmaceuticals Presents Positive Data on Immuno-Oncology Candidate at AACR 2025 Annual Meeting

Tonix Pharmaceuticals presents positive data supporting TNX-1700, its lead immuno-oncology candidate, at AACR 2025 Annual Meeting. Fusion protein TFF2 reduces immunosuppressive neutrophils in gastric cancer models. Promising results show potential for enhanced anti-tumor immune responses.

This news matters as it highlights the promising results of TNX-1700 in treating gastric cancer, showing the potential for improved anti-tumor immune responses. The development of innovative therapies targeting the tumor microenvironment is crucial for advancing cancer treatment and improving patient outcomes.